Belzutifan plus lenvatinib show promise as a second-line treatment for advanced kidney cancer
A recent study, called the Phase 3 LITESPARK-011 trial, looked [...]
Pembrolizumab plus belzutifan combination shows promise as an adjuvant treatment for kidney cancer
A large phase 3 clinical trial tested two medicines, pembrolizumab [...]
Kidney Cancer Highlights from ESMO 2025
This year’s European Society for Medical Oncology (ESMO) Congress was [...]
Kidney cancer microscope cuts patient waits in Cambridge
The kidney cancer clinic at Addenbrooke's Hospital in Cambridge is [...]
New treatment, casdatifan, shows promise in previously treated kidney cancer
A new treatment called casdatifan showed promising responses in a [...]
Kidney cancer cases are projected to double by 2050
Lifestyle risk factors such as obesity, smoking, lack of exercise, [...]
KIM-1 as a potential biomarker for kidney cancer
Currently, the search for a reliable test to identify patients [...]
Stoptober is back!
Because smoking is one of the main risk factors for [...]
Audit of NHS shows only 1% of kidney cancer patients are enrolled in clinical trials
We are pleased to announce the publication of the second [...]
Impact of first-line combination treatment on outcomes of second-line TKI in advanced kidney cancer
There is limited information on the outcomes of patients who [...]
